市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | GH Research PLC | 看跌 | 看跌 |
AIStockmoo 评分
2.1
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 2.13 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 33.88% |
| 机构持股比例 | 52.11% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 32.00 (Guggenheim, 186.23%) | 购买 |
| 32.00 (Stifel, 186.23%) | 购买 | |
| 中 | 31.50 (181.75%) | |
| 低 | 14.00 (Cantor Fitzgerald, 25.22%) | 购买 |
| 平均值 | 27.25 (143.74%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 11.59 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 13 Mar 2025 | 32.00 (186.23%) | 购买 | 10.88 |
| RBC Capital | 07 Mar 2025 | 31.00 (177.28%) | 购买 | 10.50 |
| Stifel | 27 Feb 2025 | 32.00 (186.23%) | 购买 | 10.65 |
| Cantor Fitzgerald | 13 Feb 2025 | 14.00 (25.22%) | 购买 | 14.31 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 27 Feb 2025 | 公告 | GH Research Reports Full Year 2024 Financial Results and Provides Business Updates |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合